descriviamo una ragazza di 17 anni con anemia emolitica, come presentazione di malattia di Wilson. la diagnosi è basata sui risultati della ceruloplasmina sierica < 20 mg/dl, presenza di anello di Kayser-Fleischer e anemia emolitica Coombs-negativa. i test genetici hanno rivelato la presenza della mutazione h1069q allo stato eterozigote. la paziente è stata trattata con acetato di zinco in monoterapia, con buona risposta mantenuta dopo 22 mesi. questo caso sottolinea l'importanza di riconoscere atipiche presentazioni cliniche della malattia di Wilson, che deve sempre essere considerata nei pazienti con anemia emolitica con test di Coombs negativo. la buona risposta clinica, nel nostro caso al trattamento con acetato di zinco in monoterapia, potrebbe prestarsi a considerare l'uso di monoterapia con zinco come terapia iniziale, anche in pazienti con malattia di Wilson sintomatici sotto stretta osservazione clinica. Studi clinici sono necessari per fornire prove dell'uso dello zinco in monoterapia, come terapia iniziale nei pazienti con malattia di Wilson sintomatici. 
Introduction
Wilson disease is a hereditary disorder characterized by a pathological accumulation of copper in tissues and organs, particularly the liver and the brain. onset of disease may occur from paediatric to adult age, with peak incidence between the second and the third decades of life. Symptoms on presentation usually include extremely variable liver disease, which may develop into cirrhosis, manifestations in the central nervous system, psychiatric symptoms and ophthalmologic signs, namely, the presence of Kayser-Fleischer rings. More rarely, other manifestations at onset include haemolytic disorders, bone injury, amenorrhea, endocrine gland alterations, as well as renal and cardiac abnormalities. 1, 2 Several treatment options for Wilson disease have been described, and guidelines have recently been published. 3 the most commonly used pharmacological therapies are chelating agents (penicillamine 4 , trientine 5 ), tetrathiomolybdate 6 or zinc-based treatments. 7, 8 Although initial d-penicillamine treatment is generally recommended in symptomatic patients, numerous, often severe, side effects can occur, requiring discontinuation in up to 30% of cases. 1, 2 especially, neurologic deterioration may appear during the initial phase of treatment with d-penicillamine. 9 A valid alternative therapy seems to be zinc, which is often used in combination with or after chelators as maintenance therapy. zinc administered exclusively as monotherapy in symptomatic patients is controversial: current recommendations call for its use after a period of chelating therapy. 3 nevertheless, there are reports in the literature on its immediate use as monotherapy in these patients. 7 , and bilateral Kayser-Fleischer rings were present for 360°. the result of 24-hours urinary copper excretion at admission was not available but fifty days after was 146,5 mcg (normal value < 50 mcg/24 h). Brain Mri was normal. liver biopsy was not performed to avoid the risk of bleeding. the coexistence of haemolytic anaemia with liver failure, low ceruloplasmin serum levels and bilateral Kayser-Fleischer rings prompted the diagnosis of Wilson disease. genetic testing, which revealed the presence of the h1069q heterozygous mutation, confirmed the diagnosis. to avoid the risk of neurological deterioration with chelating treatment, the girl was thus started on therapy with zinc acetate at the low dose of 25 mg 3 times a day and a diet with reduced copper content. After four months she was in good general conditions but KayserFleischer rings were unaltered. laboratory findings showed a decrease of ASt, an increase in PCe and improvement in the coagulation pattern. (table) Serum zinc level was 214 mg/dl (normal values: 52-144), a marker of good compliance with therapy. hepatic elastography showed an elastographic pattern compatible with F3 fibrosis (stiffness: 10 KPa). given the absence of adverse side effects, the zinc acetate dose was increased to 50 mg three times a day. Follow-up at 15 months confirmed improvement of clinical and laboratory findings, with normalisation of platelets, hb, ASt, Alt, albumin, total bilirubin, ldh, PCe, Pt ratio and Ptt ratio, as well as coagulation factors ii (93,2%), V (72,4%), Vii (76,5%), and x (75,3%), and antithrombin iii (101%). (table) 1, 12, 13, 14 , which is mainly due to oxidative damage of the red cell membrane caused by excess copper released by damaged hepatocytes. 15 in our patient, the suspicion of Wilson disease was confirmed as highly probable, with score 6 by the diagnostic scoring system based on clinical and laboratory parameters developed by Ferenci et al. 16 in our view, this case is deserving of interest given the good response achieved with zinc acetate monotherapy in a severe form of disease. the therapy of Wilson disease is aimed at reducing circulating copper and/or at decreasing copper accumulation in tissues. 1 the penicillamine represents the gold standard for therapy and the most widespread used in europe. While it is indeed effective at reducing copper levels (thanks to its copper-binding properties and elimination through urine), its use can be hampered by some major side effects: kidney and liver toxicity, bone marrow suppression 1 and, at the start of treatment, a potential irreversible worsening of neurological symptoms. 9 Brewer et al also documented a 26% incidence of neurologic worsening in patients treated with trientine. 17 Although chelating agents are recommended for initial therapy in Wilson diasease 3 , a valid alternative therapy seems to be zinc 18 : it induces the production of metallothionein, which selectively binds to copper in the cells of intestinal mucosa, prevents copper absorption and favours its faecal elimination within 7 to 8 days. 19 Moreover, zinc plays an important role in limiting copper hepatotoxicity by increasing the sequestration of free copper through binding with metallothionein. 20 in presymptomatic patients long-term studies have shown that zinc monotherapy can induce a negative copper balance and can normalise transaminase values. 21 the zinc monotherapy approach may be adopted in patients with exclusively hepatic or combined presentation, on the condition that liver disease is not advanced. 22 in symptomatic patients zinc administered exclusively as monotherapy is controversial: current recommendations call for its use after a period of chelating therapy. 3 nevertheless, there are reports in the literature on its immediate use as monotherapy in these patients. 7 ,10,11 recently, linn et al. 22 described their experience with long-term zinc monotherapy (median follow-up of 14 years) in 17 patients with Wilson disease, presentation of which was only hepatic in seven subjects, only neurologic in five, and combined in five. the authors concluded that zinc monotherapy is the therapy of choice in patients with exclusively neurological presentation considering the significant potential for neurologic deterioration with chelating agents. in our patient, the decision to not use for treatment chelating agent was prompt by the possibility of appearance of neurological compromission in patient with severe and symptomatic disease showing a very bilateral complete KF King. the choice of zinc acetate monotherapy as first treatment has thus far achieved good results. 
